ARTICLE | Clinical News
JNJ-42165279: Phase II hold
February 1, 2016 8:00 AM UTC
Johnson & Johnson’s Janssen Research & Development unit voluntarily suspended dosing in a double-blind, placebo-controlled, international Phase II trial evaluating 25 mg oral JNJ-42165279 in about 140...